Henry Schein, Inc. (NASDAQ:HSIC) Stock Holdings Lifted by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lifted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 19.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 5,403 shares of the company’s stock after buying an additional 895 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Henry Schein were worth $374,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Olstein Capital Management L.P. increased its position in shares of Henry Schein by 17.2% in the fourth quarter. Olstein Capital Management L.P. now owns 109,000 shares of the company’s stock worth $7,543,000 after acquiring an additional 16,000 shares in the last quarter. Private Management Group Inc. increased its position in shares of Henry Schein by 5.7% in the fourth quarter. Private Management Group Inc. now owns 350,515 shares of the company’s stock worth $24,256,000 after acquiring an additional 18,882 shares in the last quarter. Equitable Trust Co. purchased a new position in shares of Henry Schein in the fourth quarter worth approximately $417,000. Savant Capital LLC increased its stake in Henry Schein by 43.9% in the 4th quarter. Savant Capital LLC now owns 4,651 shares of the company’s stock valued at $322,000 after buying an additional 1,420 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Henry Schein by 29.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,854 shares of the company’s stock valued at $1,113,000 after buying an additional 3,650 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

HSIC stock opened at $71.84 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $8.74 billion, a price-to-earnings ratio of 29.56, a P/E/G ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The firm has a 50 day moving average of $67.38 and a two-hundred day moving average of $71.48.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.10 earnings per share. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Transactions at Henry Schein

In other news, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. The trade was a 6.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. The trade was a 9.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.08% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HSIC has been the topic of several research reports. Piper Sandler dropped their price objective on shares of Henry Schein from $83.00 to $77.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 30th. Jefferies Financial Group upped their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company dropped their price objective on shares of Henry Schein from $80.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. Finally, Barrington Research dropped their price objective on shares of Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Henry Schein has a consensus rating of “Moderate Buy” and a consensus price target of $79.30.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.